ALS Directory of Information
JavaScript or Flash Player Not Detected
This ALS banner requires Flash player 7 or higher or javascript.
PLEASE NOTE:
As of November 23, 2009, ALS Canada has a new address and phone number:
3000 Steeles Avenue East, Suite 200
Markham, Ontario L3R 4T9
Phone: 905-248-2052   Fax: 905-248-2019

ALS Directory of Information

ALS Society Page ALS and Lou Gehrigs Disease Articles
Advocacy Advocacy
ALS Research ALS Research
Awareness Awareness
Caregivers Caregivers
Charity Events Charity Events
Drug Trials Drug Trials
Fundraising Fundraising
General General
Healthcare Professionals Healthcare Professionals
Press Releases Press Releases
Researchers Researchers
Volunteer Volunteer

Recent ALS Information, Research Updates, and Related Articles:
1.  Abnormal SOD1 folding is unique to familial ALS, researchers say

Mutations in the gene encoding superoxide dismutase 1 (SOD1) cause up to 20 per cent of inherited ALS cases (familial ALS). They’ve even been observed in a small fraction of sporadic cases. It has bee ◊

"Abnormal SOD1 folding is unique to familial ALS, researchers say"
2.  Swimming-based exercise preserves motor neuron function

Whether exercise predisposes to or protects against amyotrophic lateral sclerosis is a topic of ongoing debate. ◊

"Swimming-based exercise preserves motor neuron function"
3.  Stage 3 ceftriaxone trial begins

A stage 3 trial has begun studying the efficacy of ceftriaxone, to see if it prolongs survival and/or slows decline in function in patients living with ALS. ◊

"Stage 3 ceftriaxone trial begins"
4.  Synapse formation can be triggered artificially

The formation of synapses – the junctions through which neurotransmitters relay chemical signals allowing neurons to communicate information – typically requires contact between presynaptic and postsy ◊

"Synapse formation can be triggered artificially"
5.  Phase 3 talampanel trial begins

Talampanel, a drug currently not approved in Canada or the United States, is undergoing an international Phase 3 trial involving 500 patients with ALS in centres across Europe, Canada and the US. In a ◊

"Phase 3 talampanel trial begins"